Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 851-858

  Kitchens, Carolyn A ^a,b   McDonald, Peter R ^a,b   Shun, Tong Ying ^b   Pollack, Ian F ^c   Lazo, John S ^a,b,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOT11 PROTEIN; ADSL PROTEIN; AKT3 PROTEIN; ANKRD30A PROTEIN; BTN3A2 PROTEIN; CASPASE 3; CASPASE 7; CYTOCHROME C; DHFRL1 PROTEIN; FUK PROTEIN; GENE PRODUCT; GLUTATHIONE TRANSFERASE A1; HSD11B1L PROTEIN; ITPR3 PROTEIN; KDELR1 PROTEIN; LOC136242 PROTEIN; NAVITOCLAX; NEIL3 PROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; NIT1 PROTEIN; NRAS PROTEIN; PMM2 PROTEIN; POLR1A PROTEIN; PRDX6 PROTEIN; PROTEIN BCL XL; PROTEIN CDC42; SERPINA3 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINBLASTINE;

ACOT11 GENE; ADSL GENE; AKT3 GENE; ANKRD30A GENE; APOPTOSIS; ARTICLE; BCL XL GENE; BTN3A2 GENE; CANCER CELL CULTURE; CDC42 GENE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DHFRL1 GENE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; FUK GENE; GLIOBLASTOMA; GSTA1 GENE; HIGH THROUGHPUT SCREENING; HSD11B1L GENE; HUMAN; HUMAN CELL; ITPR3 GENE; KDELR1 GENE; LOC136242 GENE; LUNG NON SMALL CELL CANCER; MITOCHONDRION; NEIL3 GENE; NIT1 GENE; NOS1 GENE; NRAS GENE; PMM2 GENE; POLR1A GENE; PRDX6 GENE; PRIORITY JOURNAL; PROCR GENE; PROTEIN LOCALIZATION; RAB9A GENE; SDHA GENE; SERPINA10 GENE; SERPINA3 GENE; SERPINB13 GENE; SPINK1 GENE; TRANSIENT TRANSFECTION; UGT1A9 GENE; UGT2B17 GENE; WARS2 GENE; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, BCL-2; GLIOBLASTOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSFECTION; TUBULIN MODULATORS; VINBLASTINE;

EID: 81555222837     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184879     Document Type: Article

References (36)

1. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, et al. (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66:869-880.
2. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, et al. (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7:3265-3274.
3. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, and Bigner DD (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061-1083.
4. Benjamini Y and Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57:289-300.
5. Benjamini Y and Hochberg Y (2000) On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Statist 25:60-83.
6. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, et al. (2009) Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6:569-575.
7. Castilla C, Congregado B, Chinchón D, Torrubia FJ, Japón MA, and Sáez C (2006) Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 147:4960-4967. (Pubitemid 44402203)
8. Chung N, Zhang XD, Kreamer A, Locco L, Kuan PF, Bartz S, Linsley PS, Ferrer M, and Strulovici B (2008) Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen 13:149-158. (Pubitemid 351248688)
9. Devlin B, Roeder K, and Wasserman L (2003) False discovery or missed discovery? Heredity 91:537-538. (Pubitemid 38012605)
10. Dumontet C and Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803.
11. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, and De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238-1241. (Pubitemid 43905604)
12. Feun LG, Savaraj N, and Landy HJ (1994) Drug resistance in brain tumors. J Neurooncol 20:165-176. (Pubitemid 24309911)
13. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, and Montegomrey W (1998) Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 13:839-848. (Pubitemid 28435362)
14. Giannakakou P, Sackett D, and Fojo T (2000) Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J Natl Cancer Inst 92:182-183. (Pubitemid 30099777)
15. Guicciardi ME and Gores GJ (2009) Life and death by death receptors. FASEB J 23:1625-1637.
16. Hockenbery DM (2010) Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51:476-489.
17. Hopkins AL and Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730. (Pubitemid 37361545)
18. Iorns E, Lord CJ, Turner N, and Ashworth A (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6:556-568. (Pubitemid 47019444)
19. Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. (Pubitemid 38525281)
20. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698.
21. Kang MH and Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126-1132.
22. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, and Haber M (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61:5803-5809. (Pubitemid 32769098)
23. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I, and Flavell RA (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847-851. (Pubitemid 43228848)
24. Li R, Zang Y, Li C, Patel NS, Grandis JR, and Johnson DE (2009) ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 75:1231-1239.
25. Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, et al. (2008) A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res 14:2732-2739.
26. Liu R, Page C, Beidler DR, Wicha MS, and Núñez G (1999) Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 155:1861-1867.
27. Parney IF and Chang SM (2003) Current chemotherapy for glioblastoma. Cancer J 9:149-156.
28. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, and Doyle LA (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429-433. (Pubitemid 29128278)
29. Shiva S, Brookes PS, Patel RP, Anderson PG, and Darley-Usmar VM (2001) Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc Natl Acad Sci USA 98:7212-7217. (Pubitemid 32567928)
30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. (Pubitemid 40349501)
31. Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, and Lazo JS (2010) Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods 185:204-212.
32. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, et al. (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:3854-3861. (Pubitemid 40685606)
33. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, and Wicha M (2002) Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 112:638-644. (Pubitemid 34285929)
34. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428.
35. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819. (Pubitemid 46582032)
36. Willingham AT, Deveraux QL, Hampton GM, and Aza-Blanc P (2004) RNAi and HTS: exploring cancer by systematic loss-of-function. Oncogene 23:8392-8400. (Pubitemid 39540721)